Prolonged survival in patients with lung cancer with diabetes mellitus

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages 1810-1817

  Hatlen, Peter ^a,b   Grønberg, Bjørn Henning ^a,b   Langhammer, Arnulf ^c   Carlsen, Sven M ^a,b   Amundsen, Tore ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Diabetes mellitus; Lung cancer; Survival

Indexed keywords

CARBOPLATIN; GEMCITABINE; PEMETREXED;

ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL TIME;

EID: 80054945312     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822a75be     Document Type: Article

References (24)

1. Cancer in Norway 2008, Institute of population based Cancer research 2008 [cited January 2, 2010]; Available from: http://www.kreftregisteret.no/Global/ 26-01-2010%20Dok%20til%20web%20ferdig.pdf.
2. Blanco JA, Toste IS, Alvarez RF, et al. Age, comorbidity, treatment decision and prognosis in lung cancer. Age Ageing 2008;37:715-718.
3. Firat S, Bousamra M, Gore E, et al. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;52:1047-1057. (Pubitemid 34219026)
4. Firat S, Byhardt RW, Gore E. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002;54:357-364. (Pubitemid 35286798)
5. Girones R, Torregrosa D, Gómez-Codina J, et al. Prognostic impact of comorbidity in elderly lung cancer patients: use and comparison of two scores. Lung Cancer 2011;72:108-113.
6. Ganti AK, Siedlik E, Marr AS, et al. Predictive ability of Charlson comorbidity index on outcomes from lung cancer. Am J Clin Oncol 2011;Epub ahead of print.
7. De Giorgio R, Barbara G, Cecconi A, et al. Diabetes is associated with longer survival rates in patients with malignant tumors. Arch Intern Med 2000;160:2217. (Pubitemid 30482731)
8. Hanbali A, Al-Khasawneh K, Cole-Johnson C, et al. Protective effect of diabetes against metastasis in patients with non-small cell lung cancer. Arch Intern Med 2007;167:513. (Pubitemid 46425669)
9. Satoh H, Ishikawa H, Kurishima K, et al. Diabetes is not associated with longer survival in patients with lung cancer. Arch Intern Med 2001;161: 485. (Pubitemid 32116572)
10. Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Impact of comor-bidity on lung cancer survival. Int J Cancer 2003;103:792-802. (Pubitemid 36113249)
11. Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-841.
12. Vasic L. Locally advanced non-small cell lung cancer-pretreatment prognostic factors: disease stage, tumor histopathological characteristics, the patient-related factors. Arch Oncol 2007;15:19-23. (Pubitemid 350218857)
13. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008;300:2754-2764.
14. Chu CK, Mazo AE, Goodman M, et al. Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol 2010;17:502-513.
15. Coughlin SS, Calle EE, Teras LR, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004;159:1160-1167. (Pubitemid 38747263)
16. Huo TI, Hsu CY, Huang YH, et al. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int 2010;30:198-207.
17. HUNT 2010 [cited April 1, 2010]; Available from: http://www.ntnu.no/dmf/ hunt/.
18. Gronberg BH, Bremnes RM, Fløtten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-3224.
19. Norwegian Cause of Death Registry at Statistics 2011 [cited April 18, 2011]; Available from: http://www.ssb.no/english/subjects/03/01/10/nos- dodsarsak-en/.
20. SEER. National Cancer Institute, Fact sheets: Lung and bronchus 2011 [cited April 10, 2011]; Available from: http://seer.cancer.gov/statfacts/html/ lungb.html.
21. Basu B, Olmos D, de Bono JS. Targeting IGF-1R: throwing out the baby with the bathwater? Br J Cancer 2011;104:1-3.
22. Karp DD, Pollak MN, Cohen RB, et al. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol 2009;4:1397-1403.
23. Neal JW, Sequist LV. Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol 2010;11: 36-44.
24. Macleod U, Pollak MN, Cohen RB, et al. Risk factors for delayed presentation and referral of symptomatic cancer: evidence for common cancers. Br J Cancer 2009;101(suppl 2):S92-S101.